Obesity Drugs
60 articles on Obesity Drugs, researched and written by the Shotlee Editorial Team from primary sources.
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.
8 min read
Novo Nordisk Sues Eli Lilly, Alleging Misleading Advertising of Obesity Drugs
Novo Nordisk has filed a lawsuit against Eli Lilly in New Jersey, claiming deceptive advertising regarding GLP-1 and dual-agonist weight loss medications.
7 min read
Pfizer's Berobenatide: A New Monthly GLP-1 for Weight Loss?
Pfizer's investigational GLP-1 receptor agonist, berobenatide, has shown promising results in Phase 2b trials for weight loss. This article delves into the data, its implications for obesity treatment, and what it means for Pfizer's investment outlook.
7 min read
Ozempic & Wegovy: Unlocking the Brain's Fading Appetite Signals
A groundbreaking study reveals that the effectiveness of semaglutide, the active ingredient in popular weight loss medications like Ozempic and Wegovy, may be linked to the duration and intensity of chemical signals within specific brain cells. This research sheds light on why weight loss can plateau and offers clues for developing more sustained and effective future therapies.
6 min read
Wegovy and Eye Stroke Risk: What You Need to Know
A recent study has raised questions about a rare but serious eye condition linked to Wegovy. Learn more about ischemic optic neuropathy (ION) and what this research means for patients using GLP-1 medications.
7 min read
Retatrutide Breakthrough: Can This Molecule Rival Gastric Bypass Surgery?
New data suggests Eli Lilly's retatrutide could deliver up to 28% weight loss, potentially rivaling bariatric surgery. Learn about efficacy and safety.
8 min read
Eli Lilly: The Obesity Stock to Buy and Hold for Durability
The weight management sector is a multi-billion dollar market today, not a future opportunity. Eli Lilly, with its groundbreaking tirzepatide (Zepbound), is poised for sustained growth and profitability, making it a compelling investment for those prioritizing durability and real earnings.
7 min read
GLP-1 Obesity Drugs & Exercise: The Essential Partnership
While GLP-1 agonists offer remarkable weight loss, a new perspective highlights why exercise remains indispensable for long-term success and health benefits, addressing challenges in patient adherence.
7 min read
Obesity Drug Coverage Restrictions Force Patients to Pivot
Tight insurance restrictions on obesity drugs are turning doctors into financial advisors and patients into strategists. With coverage limits on Zepbound favoring Wegovy, many are pivoting to compounded alternatives at $300/month versus $450 for brand names. Explore the real challenges and solutions from experts and patients.
5 min read
Obesity Drug Coverage Restrictions Force Patients to Pivot
For Meghan Lena, losing coverage for Zepbound felt devastating after losing 50 pounds. Now, GoodRx reports 12 million people will lose access to Zepbound and Wegovy from 2025-2026 due to insurance changes. Patients are pivoting to alternatives amid rising restrictions and costs.
8 min read
How to Keep Weight Off After Ozempic: Proven Strategies
Stopping Ozempic often leads to weight regain—up to 7% in trials or two-thirds within a year. While continuing semaglutide helps sustain losses, lifestyle changes and maintenance dosing offer alternatives. Work with your healthcare team for a personalized plan to keep the weight off long-term.
6 min read
Beyond GLP-1Rs: Emerging Targets to Surge 50-Fold in Obesity Market
While GLP-1R agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) dominate the obesity market, non-GLP-1R targets are poised for explosive growth. Sales for these alternatives are expected to surge almost 50-fold from $310m in 2026 to $15.5bn in 2031, driven by calcitonin receptor drugs. This diversification signals a reshaping of the $172.6bn obesity pharmaceutical landscape by 2031.
5 min read
China's Pharma Dominance Is Just Beginning
The pharmaceutical world is shifting: China has surged past the US in early-stage drug research, with programs jumping over 600% since 2015. This rapid growth promises cheaper, innovative treatments like advanced obesity drugs potentially better than Ozempic—but raises questions on access and geopolitics for patients worldwide.
5 min read
Popular Weight Loss Drugs May Cause Hidden Muscle Loss, Study Finds
Popular drugs like semaglutide and tirzepatide are transforming weight loss for type 2 diabetes and obesity patients. But a new UNC study warns of hidden muscle loss that could impact strength and mobility. Here's what the research means for safe, healthy weight management.
5 min read
EU Approves Easier Wegovy Delivery, Easing Cold Chain Rules
Novo Nordisk has won EU regulatory approval to ease cold chain requirements for Wegovy injections, marking the first GLP-1 therapy in Europe with such delivery flexibility. The change allows a 48-hour window without refrigeration from pharmacies to patients, streamlining distribution and enhancing access. This aligns with trends in direct-to-patient models and complements recent subscription programs for better affordability.
5 min read
Why Fitness Bros Are Buzzing About Retatrutide Weight-Loss Peptide
Fitness enthusiasts and longevity experts are raving about Retatrutide, the new triple-agonist weight-loss peptide dubbed 'the ultimate good' by influencers. Outshining GLP-1 drugs like Ozempic, it targets three receptors for superior fat reduction. As phase 3 trials advance toward FDA approval, here's why it's generating massive buzz.
6 min read
India's 'Mounjaro Brides': Weight-Loss Injections in Pre-Wedding Prep
In India, 'Mounjaro brides' are using weight-loss injections as part of pre-wedding rituals, driven by intense societal expectations. Clinics like Klarity Skin Clinic offer specialized packages, while doctors report a surge in queries from brides and grooms. This trend highlights both the drugs' popularity and the need for medical supervision.
5 min read
Wegovy Pill Shows Greater Weight Loss Than Foundayo in Novo Study
Novo Nordisk's latest comparison study claims its Wegovy pill delivers superior weight loss compared to Eli Lilly's newly approved Foundayo tablet. The ORION analysis shows a 3.2 percentage point edge for oral semaglutide, plus lower discontinuation rates due to side effects. As oral GLP-1s compete, discover the key findings and implications for patients.
6 min read
Biggest Mistake GLP-1 Users Make, Doctor Says
A surge in GLP-1 drug use has millions turning to shots like Ozempic or pills like Wegovy for weight loss, but doctors warn of a critical error. The biggest mistake? Thinking the prescription is enough without lifestyle changes. A study of 98,000 veterans shows combining GLP-1s with healthy habits slashes cardiovascular risks by 43%.
6 min read
Ajanta Pharma, Sun Pharma Poised for GLP-1 Opportunity in India Market Shift
India's metabolic therapy market is shifting dramatically after semaglutide's patent expiry, slashing prices by 85-90% and unlocking demand for 75-80 million obese individuals. Ajanta Pharma gears up for generic semaglutide launch, while Sun Pharma leverages innovations for sustained growth. Analysts forecast the GLP-1 segment scaling to INR34-67 billion in 3-5 years amid rising specialist adoption.
4 min read
DCGI Intensifies Crackdown on Unauthorized GLP-1 Weight-Loss Drug Sales
India's DCGI is cracking down harder on the unauthorized sale of GLP-1 weight-loss drugs amid rising generic variants. Inspections at online pharmacies, wholesalers, and clinics aim to prevent misuse that could lead to serious health risks. Patients must seek prescriptions only from qualified endocrinologists or specialists.
4 min read
GLP-1 Drugs Surge: Healthy Habits Still Essential for Best Results
Demand for GLP-1 drugs like Wegovy and Zepbound is booming, with 1 in 8 Americans now using them. But experts warn: medication alone isn't enough—pairing with healthy habits like protein-rich meals, exercise, and sleep amplifies weight loss and health gains, per recent studies.
6 min read
Low-Cost Semaglutide Generics Coming to India as Patent Expires
India's Semaglutide patent expires March 20, opening doors for low-cost generics from pharma giants like Zydus, Torrent, Sun Pharma, and Dr. Reddy's. With over 23% of women and 22% of men overweight per NFHS-5, and 45 crore adults projected obese by 2050, affordable options could reshape the fight against obesity and diabetes. Discover the price revolution and challenges ahead.
5 min read
The Quest for Oral GLP-1s: History and Innovations
For decades, GLP-1 receptor agonists like Ozempic have transformed diabetes and obesity treatment via injections, but patients crave oral options. This guide traces the scientific quest for oral GLP-1s, from early discoveries and Gila monster breakthroughs to Rybelsus challenges and promising algae-based innovations. Understand the barriers and what's next for affordable, pill-based metabolic health.
5 min read
GLP-1 Drugs Fuel Sauce, Spice M&A Boom as Taste Buds Dull
The surge in GLP-1 drug use among 12% of Americans is upending the food industry, with sauce and spice makers like Bachan's and Tapatio attracting high-value deals. As these medications dull taste buds and spur lean protein consumption, condiment companies are seeing explosive growth. Fast-food giants face billions in losses while flavor enhancers thrive.
5 min read
CDSCO Advisory Curbs Misleading Promotion of GLP-1 Obesity Drugs
India's CDSCO has issued a strict advisory against misleading promotions of prescription obesity drugs like GLP-1 receptor agonists. The regulator targets indirect ads, exaggerated claims, and efforts undermining lifestyle changes. This move reinforces ethical marketing and patient safety in obesity treatment.
4 min read
Novo, Hims End GLP-1 Feud, Partner Again on Wegovy
The months-long GLP-1 feud between Novo Nordisk and Hims & Hers Health is over, with a new partnership to sell Wegovy via Hims' telehealth platform expected Monday. Following a recent lawsuit over copycat drugs, shares surged: Hims nearly 40%, Novo 2% after-hours. Analysts call it a surprise positive for expanded market reach.
5 min read
Study: GLP-1 Drugs May Fight Addiction Across Major Substances
Patients on GLP-1 drugs like Ozempic report losing interest in cigarettes, alcohol, and more without effort. A physician-led study of over 600,000 VA patients reveals these medications cut addiction-related deaths by 50% and prevent new substance use disorders. This could transform treatment for alcohol, opioids, cocaine, cannabis, and nicotine.
5 min read
20% of Eligible Youth Prescribed GLP-1 RAs, Study Finds
Just 20% of youth eligible for GLP-1 receptor agonists due to obesity are actually prescribed these medications, according to a recent Pediatrics study. Prescribing favors older adolescents with higher BMI and specific racial groups, but interruptions due to cost affect nearly two-thirds. This highlights gaps in access to promising obesity treatments for teens.
5 min read
Zydus' ZYOG1: Oral GLP-1 Ahead of Ozempic by 15 Years
Fifteen years before Ozempic sparked the GLP-1 revolution, Zydus Lifesciences in India developed ZYOG1, a promising oral GLP-1 agonist. Showing preclinical benefits for glucose control, weight loss, and a clean safety profile, it earned phase I trial approval in 2010—but was shelved amid high costs. This untold story highlights India's early edge in peptide therapy.
5 min read
Novo Nordisk Stock Erases Wegovy Gains After CagriSema Miss
Novo Nordisk's stock has erased the last of its Wegovy-driven gains in a brutal week, down 21% after next-gen obesity drug CagriSema underperformed rivals. Despite 20.2% weight loss in trials, analysts downgrade amid patent cliffs and competition from Eli Lilly's tirzepatide. The company's pivot to oral Wegovy offers hope, but diversification pressures mount.
5 min read
Ozempic-Like Drugs in India May Drop 50% in Price from March 2026
Semaglutide-based weight-loss drugs like Ozempic and Wegovy are set for a price revolution in India, with generics launching after patent expiry on March 20, 2026, potentially halving costs. Domestic giants like Sun Pharmaceutical and Dr. Reddy's are gearing up to make these GLP-1 therapies more affordable amid rising obesity rates. This shift could transform access to effective treatments for diabetes and weight management.
5 min read
Tirzepatide Activates Brown Fat to Burn Calories, Mouse Study Shows
Tirzepatide doesn't just curb hunger—it may directly rev up fat-burning brown adipose tissue, according to a groundbreaking mouse study. Researchers separated its metabolic effects from simple calorie restriction, uncovering benefits for energy expenditure and blood glucose control. This could pave the way for more effective obesity therapies.
6 min read
NHS Pays GPs Incentives for Mounjaro, Wegovy Prescriptions
The UK Government has announced financial incentives for GPs to boost prescriptions of weight-loss injections Mounjaro and Wegovy on the NHS. Eight months into the mass rollout, not all practices are participating, prompting £25 million in funding for fairer access. Health Secretary Wes Streeting calls it a 'game changer' for obesity, but experts warn of workload risks.
6 min read
Viking Therapeutics Shares Surge 12% as Novo's CagriSema Stumbles
Shares of Viking Therapeutics surged approximately 12% on Monday following a clinical setback for Novo Nordisk's next-generation obesity drug CagriSema, which underperformed Eli Lilly's Tirzepatide in a pivotal Phase 3 trial. This shift highlights intensifying competition in the GLP-1 obesity market. Investors are eyeing Viking's VK2735 as a promising contender.
5 min read
Eli Lilly Grabs Biggest Slice of GLP-1 Gold Rush Over Ozempic
Eli Lilly has overtaken Novo Nordisk in the GLP-1 gold rush, with Mounjaro and Zepbound now holding 60% of the U.S. market versus Ozempic and Wegovy's 39%. Backed by blockbuster revenue growth and superior weight loss results in head-to-head studies, Lilly's tirzepatide drugs are reshaping obesity and diabetes treatment. Investors and patients alike are taking notice of this shift.
5 min read
Big Food Invests Millions in Rebrands as GLP-1 Drugs Reshape Demand
Global food giants like PepsiCo and Coca-Cola are ramping up investments in rebranded, protein-rich products as GLP-1 drugs suppress appetite and alter eating habits across 20% of U.S. households. With potential $12 billion in lost snack sales over the next decade, companies are shifting to smaller portions and nutrient-dense options. This adaptation highlights the lasting ripple effects of obesity medications on the food industry.
5 min read
Dr Reddy's Wegovy Generic Set for 50-60% Discounts in India
Indian drugmaker Dr Reddy's Laboratories is gearing up to launch a generic version of Novo Nordisk's Wegovy at prices up to 60% lower than the original. Co-chairman G V Prasad confirmed 50-60% discounts are feasible as semaglutide's patent nears expiry in March. This could reshape access to weight-loss treatments in India's competitive market.
5 min read
Novo Nordisk to Meet US Wegovy Pill Demand First, CEO Doustdar Says
Novo Nordisk is prioritizing the US market for its popular Wegovy pill to prevent shortages like those seen with injectable semaglutide. CEO Mike Doustdar emphasized a country-by-country rollout strategy amid legal battles against compounders and competition from Eli Lilly. With 246,000 US users already on the oral obesity drug, supply stability is key.
5 min read
Knockoff GLP-1 Market Still the Wild West: Hims Fallout
Telehealth firm Hims & Hers sparked chaos by launching a cheap compounded Wegovy pill, only to yank it days later amid FDA crackdowns and a Novo Nordisk lawsuit. This incident highlights the ongoing Wild West in the knockoff GLP-1 market. Despite resolved shortages for Wegovy and Zepbound, unregulated compounded drugs remain widely available.
5 min read
Ozempic & Weight Loss Drugs: Benefits, Risks, Long-Term Effects
Ozempic, the semaglutide injection revolutionizing obesity treatment, delivers 15-20% weight loss but comes with gastrointestinal side effects and muscle loss risks. The SELECT trial shows a 20% drop in heart attacks and strokes for high-risk patients. Discover benefits, hidden risks, and long-term strategies for sustained success.
7 min read
Novo Nordisk Sues Hims & Hers Over Semaglutide Patent
Novo Nordisk has filed a lawsuit against Hims & Hers Health Inc., accusing the telehealth company of breaching its U.S. patent on semaglutide used in blockbuster obesity drugs like Ozempic and Wegovy. Despite Hims scrapping plans for a copycat Wegovy pill, Novo claims the compounded versions remain dangerous and infringing. This legal battle highlights growing tensions over compounded GLP-1 drugs post-shortage.
5 min read
Weight-Loss Price Wars Upend Big Pharma's Model
Two years ago, GLP-1 prescriptions cost over $1,000 monthly for uninsured patients. Now, Wegovy's pill starts at $149, flipping Big Pharma's playbook amid fierce price wars. As Novo Nordisk forecasts sales drops and Eli Lilly surges, discover how consumer demand is reshaping obesity treatments.
6 min read
GLP-1 Obesity Drugs Complicate Life for People with Disordered Eating
Jason Krynicki, once bullied for obesity, now battles anorexia while on Zepbound, fearing weight regain if he stops. GLP-1 drugs curb appetite effectively but complicate lives for those with disordered eating, often without proper screening. Experts highlight risks and call for caution in a weight-stigma culture.
5 min read
Roche CT-388: GLP-1/GIP Shot Rivals Zepbound in Phase 2
Roche is advancing CT-388, a dual GLP-1/GIP agonist, after Phase 2 results showed impressive weight loss comparable to Eli Lilly's Zepbound. With the obesity market booming, can this injectable stand out against Wegovy and emerging orals? Dive into the data and what it means for patients.
4 min read
Medicare GLP-1 Coverage 2026: Wegovy, Zepbound Guide
Medicare is breaking its long-standing rule against covering weight loss drugs like Wegovy and Zepbound through a new GLP-1 initiative. Starting with a bridge phase in July 2026, eligible beneficiaries could pay just $50 monthly copays—if they act now. This guide explains the changes, requirements, and clinical context for GLP-1 therapy.
4 min read
GLP-1 Nutrition Boosters: Pharma & Startup Innovations
GLP-1 medications like Ozempic and Wegovy are transforming weight management, but side effects like gut issues and muscle loss demand smart support. Nutrition and pharma startups are stepping up with targeted innovations to enhance results and minimize risks. Learn how binding proteins, protein enzymes, and novel inhibitors create a comprehensive ecosystem for long-term success.
4 min read
Novo Nordisk vs Eli Lilly: GLP-1 Drugs Showdown
Novo Nordisk and Eli Lilly dominate the GLP-1 market with powerhouse drugs like Wegovy and Zepbound. But which offers better weight loss results, tolerability, and future potential? This guide breaks down the science, clinical trials, and real-world factors to help you decide.
5 min read
Oral GLP-1s: Orforglipron vs. Oral Wegovy Explained
The race for oral GLP-1 medications is intensifying, with Novo Nordisk's oral Wegovy now approved and Eli Lilly's orforglipron facing a brief FDA review extension. These pill-based alternatives to injections promise easier access for weight loss and metabolic health. Learn how they stack up in efficacy, tolerability, and real-world impact.
4 min read
Investor $100K Bet: Altimmune Pemvidutide vs Eli Lilly
Altimmune shares surged 35.4% after FDA granted Breakthrough Therapy Designation to pemvidutide for MASH treatment. Reddit investors, including one with a $100K position, hail it as a game-changer versus Eli Lilly's Mounjaro and Zepbound. This highlights promise in metabolic disease therapies.
2 min read
Wegovy Pill: 18,410 Prescriptions in First Full Week
Novo Nordisk's Wegovy pill recorded 18,410 U.S. prescriptions in its first full week after launch, surpassing other GLP-1 starts. Investors eye its edge over Eli Lilly in the competitive obesity market. Oral treatments offer needle-free flexibility for patients.
1 min read
Matt Cooper Defends Ozempic Users: Early Adopter Story
Radio host Matt Cooper reveals his journey as an early Ozempic adopter for type 2 diabetes. He defends users struggling with weight, sharing how the GLP-1 drug curbs appetite and led to gallbladder removal. Learn from his candid experiences on semaglutide benefits and challenges.
2 min read
Seoul Hoards 66% of GLP-1 Supply as High-Risk Areas Lack
Two-thirds of South Korea's GLP-1 obesity drugs, including Wegovy and Mounjaro, flow to Greater Seoul despite higher obesity rates elsewhere. This supply imbalance raises alarms over access for high-risk patients. Data reveals stark regional disparities in distribution.
2 min read
GLP-3s, Monthly Pens: Next Obesity Drugs Leap in 2026
GLP-1 drugs like Ozempic and Mounjaro have revolutionized weight loss, and the next wave—GLP-3s such as retatrutide—promises even greater results. Eli Lilly's phase 3 trial revealed up to 28.7% body weight loss in 48 weeks. Discover monthly injections, oral pills, and emerging indications for 2026.
3 min read
South Africa's 2026 Agenda Spotlights GLP-1 Obesity Drugs
One-third of South Africans live with obesity, driving new clinical guidelines that endorse GLP-1 drugs like Ozempic, Mounjaro, and Wegovy. These medications lower blood sugar, slow digestion, and promote fullness but face affordability barriers. Experts urge political action for broader access.
4 min read
FDA Expedited Drug Program Raises Safety Concerns for Obesity Meds
The FDA's Commissioner's National Priority Voucher program aims to approve drugs in as little as one month, including anti-obesity medications. Staff and experts raise alarms over skipped steps, legal risks, and safety issues, like patient deaths in trials. Traditional six-to-10-month reviews ensure rigorous safety checks for GLP-1 drugs.
4 min read
AbbVie: Amylin Alternative to GLP-1 for Obesity Treatments
AbbVie is bolstering its obesity portfolio with GUBamy, an amylin-based drug from Gubra as a GLP-1 alternative. Unlike gut hormone-mimicking GLP-1s like Wegovy and Zepbound, amylin targets pancreatic hormones for improved tolerability and muscle retention. The company eyes long-term efficacy amid a $150B market boom.
1 min read
Health Minister Advances Wegovy's PBS Inclusion
The Australian government is set to partner with manufacturers to make Wegovy available on the Pharmaceutical Benefits Scheme for obesity management. This follows expert recommendations from the PBAC, addressing high private costs and equity in healthcare access.
2 min read
Key Insights on Weight Loss Medications for 2026
Weight loss medications such as Wegovy and Zepbound are set to become more accessible and affordable, moving beyond high costs and weekly shots. New pill forms offer alternatives for those avoiding injections, with significant developments in GLP-1 treatments expected. Advances in pricing and access programs aim to broaden availability for patients.
6 min read
Reasons for the Hype Around Wegovy -- And Its Actual Significance for Investing in Novo Nordisk
Novo Nordisk has shifted its focus with Wegovy, a groundbreaking GLP-1 injection for weight management, driving significant interest and market shifts. This article explores the drug's efficacy, market forces, and potential impacts on the company's shares. Investors should consider the opportunities and risks tied to this transformative product.
6 min read